- 1/22/2021Results of RELIEF, a Phase 2a Study with BLU-5937 in Refractory Chronic Cough. The Eleventh International Virtual Cough Symposium.
En Savoir Plus - 1/22/2021BLU-5937, A Potent and Selective P2X3 Receptor Antagonist, Presents a Promising New Approach for the Treatment of Chronic Pruritus in Atopic Dermatitis Patients. The Eleventh International Virtual Cough Symposium.
En Savoir Plus - 9/21/2019BLU-5937; A Potent and Selective P2X3 Antogonist, for the Treatment of Chronic Itch: Evidence from Preclinical Studies. 2019 European Society for Dermatological Research Conference.
En Savoir Plus - 6/7/2019BLU-5937: A Highly Selective P2X3 Homotrimeric Receptor Antagonist, Exhibits Excellent Pharmacokinetic and Safety Profile Including Improved Taste Safety Profile in Healthy Subjects. 2019 American Cough Conference.
En Savoir Plus - 5/21/2019BLU-5937 a Highly Selective P2X3 Homotrimeric Receptor Antagonist with Improved Taste Safety Profile in Healthy Subjects. 2019 American Thoracic Society Conference.
En Savoir Plus - 3/20/2019BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. ELSEVIER.
En Savoir Plus
Science
Publications scientifiques